The search continues: Looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer

International Journal of Gynecological Cancer

Volumn 24, Issue 4, 2014, Pages 713-717

  Meyer, Larissa A ^a   Slomovitz, Brian M ^a,c   Djordjevic, Bojana ^b,d   Westin, Shannon N ^a   Iglesias, David A ^a   Munsell, Mark F ^b   Jiang, Yunyun ^a   Schmandt, Rosemarie ^a   Broaddus, Russell R ^b   Coleman, Robert L ^a   Galbincea, John M ^b   Lu, Karen H ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Women's Cancer Center   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Endometrial cancer; MTOR inhibitor; Predictive biomarker

Indexed keywords

BIOLOGICAL MARKER; EVEROLIMUS; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RIBOSOME PROTEIN; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; KRAS PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; PTEN PROTEIN, HUMAN; RAPAMYCIN; RAS PROTEIN; S6 KINASE; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CLINICAL TRIAL; ENDOMETRIAL NEOPLASMS; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MUTATION; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; ENDOMETRIAL NEOPLASMS; EVEROLIMUS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MUTATION; NEOPLASM GRADING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84900435582     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000118     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol. 2006;4:459-468.
3. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159-2166.
4. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol. 2009;27:328-333.
5. Maxwell GL, Risinger JI, Gumbs C, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998;58:2500-2503.
6. McCampbell AS, Harris HA, Crabtree JS, et al. Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycinYdependent endometrial hyperplasia and carcinoma. Cancer Prev Res. 2010;3:290-300.
7. Djordjevic B, Hennessy BT, Li J, et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol. 2012;25:699-708.
8. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924-930.
9. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814-824.
10. Sasaki H, Nishii H, Takahashi H, et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 1993;53:1906-1910.
11. Duggan BD, Felix JC, Muderspach LI, et al. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res. 1994;54:1604-1607.
12. Semczuk A, Berbec H, Kostuch M, et al. K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients? outcome. J Cancer Res Clin Oncol. 1998;124:695-700.
13. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011;10:558-565.
14. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116:5415-5419.
15. Oza AM, Elit L, Provencher D, et al. NCIC Clinical Trials Group. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy. J Clin Oncol. 2008;26:296s
16. Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. ASCO Meeting Abstr. 2007;25:5516.
17. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
18. Bartlett JM. Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions. Clin Breast Cancer. 2010;10:S86-S95.
19. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65:10669-10673.
20. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.
21. Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120:2858-2866.
22. Iglesias DA, Yates MS, van der Hoeven D, et al. Another surprise from metformin: novel mechanism of action via K-ras influences endometrial cancer response to therapy. Mol Cancer Ther. 2013;12:2847-2856.